Drugging the 'undruggable' cancer targets
Paper cited by one bottleneck page and 24 idea pages, indexed on Europe PMC as PubMed record 28643779 and published in Nature Reviews Cancer; the citing pages link this DOI, which is how the record was matched.
Overview
The term 'undruggable' was coined to describe proteins that could not be targeted pharmacologically. However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'. Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacologically targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies. In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.
Indexed on Europe PMC as PubMed record 28643779 (DOI 10.1038/nrc.2017.36). Matched by DOI alone: one bottleneck page and 24 idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One bottleneck page and 24 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.
Similar pages
not linked directly; found by shared links- CompanyKymera Therapeutics
Shares Find E3 ligases that only tumours have, and build degraders around them, Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Use antibodies to deliver protein-destroying drugs into the right cells.
- CompanyC4 Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, Degraders for the fusion proteins that drive childhood sarcomas, The undruggable drivers.
- CompanyNurix Therapeutics
Shares Find E3 ligases that only tumours have, and build degraders around them, Screen glue-like compounds against every cancer cell line and publish it, Use antibodies to deliver protein-destroying drugs into the right cells, The undruggable drivers.
- CompanyFrontier Medicines
Shares An open map of which cancer proteins any drug can stick to, Covalent chemistry for the RAS mutations that still have no drug, The undruggable drivers.
- CompanyMonte Rosa Therapeutics
Shares Molecular glues that break the MYC-MAX partnership, Screen glue-like compounds against every cancer cell line and publish it, The undruggable drivers.
- TechnologyPROTACs & molecular glues (targeted protein degradation)
Shares Degrade the damaged p53 protein rather than trying to repair it, Drag cancer's surface and secreted proteins to the cell's recycling bin, Instruct tumour cells to make antibodies against their own oncoprotein, Find E3 ligases that only tumours have, and build degraders around them.
- CompanyOrna Therapeutics (Eli Lilly)
Shares Instruct tumour cells to make antibodies against their own oncoprotein, mRNA-delivered MYC decoy proteins instead of MYC inhibitors.
- CompanyGenerate:Biomedicines
Shares AI-designed proteins that grip the floppy parts of cancer drivers, Macrocyclic peptides to cover protein surfaces that pills cannot.